sellNotable cluster of 9
Colin John Meyer sold $8.1M of RETA
Chief Innovation Officer at REATA PHARMACEUTICALS INC. 93,922 shares at an average of $86.72, traded Mar 2, 2023, filed Mar 6, 2023.
Warning score
60Value
$8.1M
93,922 shares
Holdings after
85,227
-52% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$8.1M at market
- +20Share of holdings soldSold 52% of holdings
- +15Cluster9 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-016380, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2023 | CConversion Class A common stock | +88,636 | - | - | 179,149 | Mar 6, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -22,752 | $85.23 | $1.9M | 156,397 | Mar 6, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -34,794 | $86.49 | $3.0M | 121,603 | Mar 6, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -19,099 | $87.55 | $1.7M | 102,504 | Mar 6, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -11,181 | $88.50 | $990k | 91,323 | Mar 6, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -810 | $90.58 | $73k | 90,513 | Mar 6, 2023 |
| Mar 3, 2023 | SOpen-market sale Class A common stock | -5,286 | $87.35 | $462k | 85,227 | Mar 6, 2023 |
| Mar 2, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -88,636 | $0.00 | $0 | 0 | Mar 6, 2023 |
| Mar 2, 2023 | MOption exercise Class B common stockderivative | +88,636 | $11.00 | $975k | 162,940 | Mar 6, 2023 |
| Mar 2, 2023 | CConversion Class B common stockderivative | -88,636 | - | - | 74,304 | Mar 6, 2023 |
Related signals
Other insiders at REATA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $808k 9,317 shares | -22% | |
| 53Moderate | REATA PHARMACEUTICALS INC | Shamim Ruff director | $481k 5,740 shares | -52% | |
| 50Moderate | REATA PHARMACEUTICALS INC | Andrea Loewen SVP, Global Regulatory Affairs | $1.6M 19,036 shares | -33% | |
| 30Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $14k 165 shares | -1% | |
| 60Notable | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $8.5M 96,996 shares | -100% | |
| 45Moderate | REATA PHARMACEUTICALS INC | Samina Khan SVP, Chief Medical Officer | $331k 3,961 shares | -9% | |
| 37Weak | REATA PHARMACEUTICALS INC | Colin John Meyer Chief Innovation Officer | $53k 621 shares | -1% | |
| 36Weak | REATA PHARMACEUTICALS INC | Michael D Wortley Chief Legal Officer | $35k 414 shares | -1% | |
| 44Moderate | REATA PHARMACEUTICALS INC | Manmeet Singh Soni COO, CFO and President | $53k 622 shares | -1% | |
| 38Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $72k 820 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.